Stock Screener App

Gratuito -

Installare

3.23

4.87% 0.15

after-market

Dopo l'orario di chiusura: 3.20 -0.03 -0.93%

Editas Medicine Inc (EDIT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EDIT Giù? Forum Previsione

Editas Medicine Inc Borsa (EDIT) Ultime notizie

Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat

Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media

Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - Kalkine Media

Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat

Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media

Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan

Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan

Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn

EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha

BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat

Boston and New York will host Editas Medicine talks this month - Stock Titan

Editas Medicine Files $400 Million Mixed Shelf - marketscreener.com

O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan

Editas Medicine (EDIT) officer flags 700-share stock sale - Stock Titan

Editas Medicine stock holds steady as investors weigh latest gene editing progress - AD HOC NEWS

Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT - MarketBeat

EDIT Price History for Editas Medicine Stock - Barchart.com

Editas Medicine Inc. (EDIT) Peer Comparison – Compare with Others - Value Research

ADAR1 Capital Management LLC Buys New Stake in Editas Medicine, Inc. $EDIT - MarketBeat

Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5%Time to Buy? - MarketBeat

Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026. - marketscreener.com

EDIT Stock Price, Quote & Chart - ChartMill

ETFs Investing in Editas Medicine, Inc. Stocks - TradingView

Editas Medicine (NASDAQ:EDIT) Trading 14.4% HigherHere's What Happened - MarketBeat

Ladenburg Thalmann Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $6 - Moomoo

EDIT Initiates Coverage On Ladenburg ThalmannRating Set to Bu - GuruFocus

Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat

367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP - MarketBeat

EDIT Q2 2026 Earnings: Narrower-than-Expected Loss Underscores Cost DisciplineRevenue Growth Report - vinanet.vn

Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus

Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan

Editas Medicine (EDIT) Slides 3.7% as Gene-Editing Stock Tests Key Support at $2.70Collar Trade - vinanet.vn

Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat

Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat

Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et

Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Singapore

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Editas Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN - TradingView

HC Wainwright Boosts Earnings Estimates for Editas Medicine - MarketBeat

Editas Medicine, Inc. (0IFK.L) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold - MarketBeat

BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo

H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000 - Stock Titan

Editas Medicine, Inc. (EDIT) director reports no share or option holdings - Stock Titan

Editas Medicine, Inc. expected to post a loss of 27 cents a shareEarnings Preview - TradingView

Editas Medicine, Inc. (0IFK.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Yahoo Finance

Editas Medicine Announces Second Quarter 2026 Results and Business Updates - The Manila Times

Editas Medicine Q2 Operating Expenses USD 30. - Moomoo

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - marketbeat.com

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Editas: Q2 Earnings Snapshot - marketscreener.com

Editas Medicine Q2 net loss narrows and beats estimates - TradingView

Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary - TradingView

Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan - Stock Titan

EDIT: EDIT-401 advances toward clinical trials with robust preclinical data and improved financials - TradingView

Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M - Stock Titan

BRIEF-Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million - TradingView

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates - Moomoo

EDIT|Editas Medicine Inc|Price:3.160|Chg%:-0.140 - TradingKey

Editas Medicine appoints Patrick Ellinor to board of directors By Investing.com - Investing.com UK

BNTX

$103.76

0.86%

INSM

$126.29

0.31%

RPRX

$63.96

0.13%

ALNY

$266.11

0.61%

ONC

$358.26

1.22%

RVMD

$210.02

0.40%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters